Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 3Salivary Gland Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1

Interventions

Fulvestrant 34Specimen Handling 31Letrozole 30Paclitaxel 23pembrolizumab 19Carboplatin 19ribociclib 18exemestane 18Capecitabine 17Trastuzumab 16Tamoxifen 16Magnetic Resonance Spectroscopy 16palbociclib 15Anastrozole 15Biopsy 14trastuzumab deruxtecan 13abemaciclib 13pertuzumab 11Radiotherapy 11Cyclophosphamide 9inavolisib 8elacestrant 8olaparib 7Taxes 7Standard of Care 7Radiation 7Mastectomy, Segmental 7Goserelin 7130-nm albumin-bound paclitaxel 7giredestrant 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Glutamate Carboxypeptidase II × 30 days × Clear all
NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡